BioAffinity Begin Period Cash Flow vs Change In Working Capital Analysis

BIAFW Stock

USD 0.57 0.13 18.57%

BioAffinity Technologies financial indicator trend analysis is way more than just evaluating BioAffinity Technologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioAffinity Technologies is a good investment. Please check the relationship between BioAffinity Technologies Begin Period Cash Flow and its Change In Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

Begin Period Cash Flow vs Change In Working Capital

Begin Period Cash Flow vs Change In Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioAffinity Technologies Begin Period Cash Flow account and Change In Working Capital. At this time, the significance of the direction appears to have strong relationship.

The correlation between BioAffinity Technologies' Begin Period Cash Flow and Change In Working Capital is 0.68. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Change In Working Capital in the same time period over historical financial statements of bioAffinity Technologies Warrant, assuming nothing else is changed. The correlation between historical values of BioAffinity Technologies' Begin Period Cash Flow and Change In Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of bioAffinity Technologies Warrant are associated (or correlated) with its Change In Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Working Capital has no effect on the direction of Begin Period Cash Flow i.e., BioAffinity Technologies' Begin Period Cash Flow and Change In Working Capital go up and down completely randomly.

Correlation Coefficient

0.68

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Change In Working Capital

The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.

Most indicators from BioAffinity Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioAffinity Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

At this time, BioAffinity Technologies' Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to climb to about 7.1 M in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.0M	2.5M	37.1K	35.3K
Depreciation And Amortization	4.8K	10.2K	249.6K	262.1K

Interest Expense Depreciation And Amortization

BioAffinity Technologies fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Non Current Liabilities Total	Inventory	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.55	-0.08	-0.51	0.78	0.56	-0.85	-0.8	0.81	0.92	0.53	-0.47	0.92	0.51	-0.54	1.0	0.97	-0.33	0.95	-0.57	0.95	0.81	-0.98	-0.5	0.98	0.56
Short Long Term Debt Total	-0.55		0.81	1.0	-0.95	-0.43	0.86	0.26	-0.27	-0.49	-0.41	0.37	-0.49	-0.4	0.34	-0.53	-0.5	0.93	-0.51	1.0	-0.56	-0.11	0.6	0.81	-0.57	-0.43
Other Current Liab	-0.08	0.81		0.84	-0.61	-0.01	0.53	-0.27	0.2	-0.09	0.0	0.05	-0.09	0.01	0.11	-0.06	0.0	0.91	-0.08	0.78	-0.09	0.45	0.12	0.83	-0.08	0.0
Total Current Liabilities	-0.51	1.0	0.84		-0.93	-0.42	0.83	0.23	-0.24	-0.45	-0.4	0.34	-0.45	-0.39	0.31	-0.48	-0.46	0.94	-0.46	0.99	-0.52	-0.07	0.56	0.82	-0.53	-0.41
Total Stockholder Equity	0.78	-0.95	-0.61	-0.93		0.55	-0.96	-0.52	0.5	0.72	0.52	-0.49	0.72	0.5	-0.5	0.77	0.73	-0.8	0.74	-0.95	0.76	0.4	-0.81	-0.77	0.8	0.55
Property Plant And Equipment Net	0.56	-0.43	-0.01	-0.42	0.55		-0.39	-0.86	0.81	0.28	1.0	0.05	0.28	1.0	-0.05	0.52	0.69	-0.12	0.35	-0.5	0.73	0.61	-0.7	-0.26	0.65	1.0
Net Debt	-0.85	0.86	0.53	0.83	-0.96	-0.39		0.49	-0.47	-0.86	-0.35	0.62	-0.86	-0.33	0.64	-0.85	-0.75	0.73	-0.87	0.86	-0.76	-0.44	0.83	0.75	-0.85	-0.39
Retained Earnings	-0.8	0.26	-0.27	0.23	-0.52	-0.86	0.49		-0.91	-0.63	-0.85	0.22	-0.63	-0.84	0.35	-0.79	-0.87	-0.08	-0.67	0.32	-0.85	-0.87	0.87	0.17	-0.86	-0.87
Accounts Payable	0.81	-0.27	0.2	-0.24	0.5	0.81	-0.47	-0.91		0.55	0.8	0.01	0.55	0.79	-0.07	0.78	0.93	-0.02	0.62	-0.33	0.93	0.89	-0.87	-0.23	0.8	0.81
Cash	0.92	-0.49	-0.09	-0.45	0.72	0.28	-0.86	-0.63	0.55		0.25	-0.7	1.0	0.23	-0.79	0.95	0.81	-0.31	1.0	-0.49	0.77	0.66	-0.85	-0.47	0.91	0.29
Non Current Assets Total	0.53	-0.41	0.0	-0.4	0.52	1.0	-0.35	-0.85	0.8	0.25		0.08	0.25	1.0	-0.02	0.49	0.67	-0.11	0.31	-0.48	0.7	0.59	-0.68	-0.23	0.62	1.0
Non Currrent Assets Other	-0.47	0.37	0.05	0.34	-0.49	0.05	0.62	0.22	0.01	-0.7	0.08		-0.7	0.09	0.82	-0.5	-0.3	0.29	-0.66	0.35	-0.23	-0.31	0.36	0.07	-0.5	0.05
Cash And Short Term Investments	0.92	-0.49	-0.09	-0.45	0.72	0.28	-0.86	-0.63	0.55	1.0	0.25	-0.7		0.23	-0.79	0.95	0.81	-0.31	1.0	-0.49	0.77	0.66	-0.85	-0.47	0.91	0.29
Net Receivables	0.51	-0.4	0.01	-0.39	0.5	1.0	-0.33	-0.84	0.79	0.23	1.0	0.09	0.23		0.0	0.47	0.65	-0.1	0.29	-0.46	0.69	0.59	-0.66	-0.22	0.6	1.0
Common Stock Shares Outstanding	-0.54	0.34	0.11	0.31	-0.5	-0.05	0.64	0.35	-0.07	-0.79	-0.02	0.82	-0.79	0.0		-0.59	-0.36	0.17	-0.74	0.33	-0.31	-0.24	0.48	0.34	-0.63	-0.06
Other Current Assets	1.0	-0.53	-0.06	-0.48	0.77	0.52	-0.85	-0.79	0.78	0.95	0.49	-0.5	0.95	0.47	-0.59		0.95	-0.31	0.97	-0.55	0.93	0.8	-0.97	-0.5	0.98	0.53
Other Stockholder Equity	0.97	-0.5	0.0	-0.46	0.73	0.69	-0.75	-0.87	0.93	0.81	0.67	-0.3	0.81	0.65	-0.36	0.95		-0.26	0.86	-0.54	0.99	0.87	-0.98	-0.44	0.95	0.7
Total Liab	-0.33	0.93	0.91	0.94	-0.8	-0.12	0.73	-0.08	-0.02	-0.31	-0.11	0.29	-0.31	-0.1	0.17	-0.31	-0.26		-0.32	0.91	-0.32	0.12	0.34	0.77	-0.3	-0.12
Total Current Assets	0.95	-0.51	-0.08	-0.46	0.74	0.35	-0.87	-0.67	0.62	1.0	0.31	-0.66	1.0	0.29	-0.74	0.97	0.86	-0.32		-0.52	0.82	0.7	-0.89	-0.48	0.94	0.36
Short Term Debt	-0.57	1.0	0.78	0.99	-0.95	-0.5	0.86	0.32	-0.33	-0.49	-0.48	0.35	-0.49	-0.46	0.33	-0.55	-0.54	0.91	-0.52		-0.6	-0.16	0.63	0.8	-0.6	-0.49
Common Stock	0.95	-0.56	-0.09	-0.52	0.76	0.73	-0.76	-0.85	0.93	0.77	0.7	-0.23	0.77	0.69	-0.31	0.93	0.99	-0.32	0.82	-0.6		0.83	-0.98	-0.51	0.93	0.73
Long Term Debt	0.81	-0.11	0.45	-0.07	0.4	0.61	-0.44	-0.87	0.89	0.66	0.59	-0.31	0.66	0.59	-0.24	0.8	0.87	0.12	0.7	-0.16	0.83		-0.79	0.05	0.78	0.62
Non Current Liabilities Total	-0.98	0.6	0.12	0.56	-0.81	-0.7	0.83	0.87	-0.87	-0.85	-0.68	0.36	-0.85	-0.66	0.48	-0.97	-0.98	0.34	-0.89	0.63	-0.98	-0.79		0.55	-0.98	-0.71
Inventory	-0.5	0.81	0.83	0.82	-0.77	-0.26	0.75	0.17	-0.23	-0.47	-0.23	0.07	-0.47	-0.22	0.34	-0.5	-0.44	0.77	-0.48	0.8	-0.51	0.05	0.55		-0.51	-0.25
Net Invested Capital	0.98	-0.57	-0.08	-0.53	0.8	0.65	-0.85	-0.86	0.8	0.91	0.62	-0.5	0.91	0.6	-0.63	0.98	0.95	-0.3	0.94	-0.6	0.93	0.78	-0.98	-0.51		0.65
Property Plant And Equipment Gross	0.56	-0.43	0.0	-0.41	0.55	1.0	-0.39	-0.87	0.81	0.29	1.0	0.05	0.29	1.0	-0.06	0.53	0.7	-0.12	0.36	-0.49	0.73	0.62	-0.71	-0.25	0.65

Click cells to compare fundamentals

BioAffinity Technologies Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioAffinity Begin Period Cash Flow vs Change In Working Capital Analysis

Begin Period Cash Flow vs Change In Working Capital

Begin Period Cash Flow vs Change In Working Capital Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Change In Working Capital

BioAffinity Technologies fundamental ratios Correlations

BioAffinity Technologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for BioAffinity Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Short Long Term Debt Total
Short Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Net Receivables	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Net Invested Capital	- 0.98	Non Current Liabilities Total
Non Current Liabilities Total	- 0.98	Common Stock
Non Current Liabilities Total	- 0.98	Other Stockholder Equity
Non Current Liabilities Total	- 0.98	Total Assets
Non Current Liabilities Total	- 0.97	Other Current Assets
Net Debt	- 0.96	Total Stockholder Equity